Carbylan Therapeutics Schedules Second Quarter 2015 Financial Results
July 28, 2015 08:30 ET
|
Carbylan Therapeutics
PALO ALTO, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies,...
Carbylan Therapeutics Provides Timeline Update for Phase 3 Clinical Program
July 15, 2015 16:05 ET
|
Carbylan Therapeutics
First Phase 3 trial, COR1.1, on track for first quarter 2016 data availability
Second Phase 3 trial, COR1.2, to enroll first patients in early 2016 with IND in first half 2016
NDA...
Carbylan Therapeutics Appoints Dr. Prem Ramiya Vice President, Pharmaceutical Development & Supply Chain
July 08, 2015 08:30 ET
|
Carbylan Therapeutics
PALO ALTO, Calif., July 8, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies,...
Carbylan Therapeutics to Present at the JMP Securities 2015 Life Sciences Conference
June 17, 2015 16:24 ET
|
Carbylan Therapeutics
PALO ALTO, Calif., June 17, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (Nasdaq:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies,...
Carbylan Therapeutics Completes Enrollment of Phase 3 Pivotal Trial for Hydros-TA
June 08, 2015 16:15 ET
|
Carbylan Therapeutics
PALO ALTO, Calif., June 8, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (Nasdaq:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies,...
Carbylan Therapeutics Announces First Quarter 2015 Financial Results
May 19, 2015 16:05 ET
|
Carbylan Therapeutics
PALO ALTO, Calif., May 19, 2015 (GLOBE NEWSWIRE) -- Carbylan® Therapeutics (Nasdaq:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination...
Carbylan Therapeutics, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
April 14, 2015 16:30 ET
|
Carbylan Therapeutics
PALO ALTO, Calif., April 14, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics, Inc. (Nasdaq:CBYL) (the "Company") today announced the closing of its initial public offering of 14,950,000 shares of its...
Carbylan Therapeutics, Inc. Announces Pricing of Initial Public Offering
April 08, 2015 18:42 ET
|
Carbylan Therapeutics
PALO ALTO, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics, Inc. (the "Company") today announced the pricing of its initial public offering of 13,000,000 shares of its common stock at...
Carbylan Therapeutics Expands Board of Directors With Three Appointments
December 30, 2014 08:30 ET
|
Carbylan Therapeutics
PALO ALTO, Calif., Dec. 30, 2014 (GLOBE NEWSWIRE) -- Carbylan Therapeutics, a pharmaceutical company focused on the development of novel and proprietary combination therapies, today announced the...